X4 Pharmaceuticals, Inc. (XFOR )

Currency in USD Disclaimer
$3.8 +$0.71 (22.98%)
Open 10/27/2025
$3.28
$4.54
$1.35
$26.82

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol XFOR
  • Company X4 Pharmaceuticals, Inc.
  • Price $3.8
  • Changes Percentage 22.98
  • Change 0.71
  • Day Low $3.28
  • Day High $4.54
  • Year High $26.82
  • Year Low $1.35
  • Market Cap $43,351,540
  • Price Avg 50 EMA (D) $3.34
  • Price Avg 200 EMA (D) $6.08
  • Exchange NASDAQ
  • Volume 22,120,377
  • Average Volume 4,042,957
  • Open $3.4
  • Previous Close $3.09
  • EPS -15.14
  • PE -0.25
  • Earnings Announcement 2025-11-07 20:00:00
  • Shares Outstanding $11,408,300

Company brief: X4 PHARMACEUTICALS, INC. (XFOR )

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

XFOR Corporation News

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

October 24, 2025 at 4:37 am ET

globenewswire.com -- BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announ...

Income Statement